Lilly to supply up to 220,000 COVID-19 antibody combo doses to European countries By Reuters
(Reuters) -Eli Lilly on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease.
Bamlanivimab plus etesevimab are the two main treatments. They can be used in patients without COVID-19.
Following authorization by Lilly, countries within the European Union/European Economic Area will be able to buy the products directly from Lilly. Lilly also said that quantities may differ depending on the local need.
Lilly explained that while many European countries previously placed orders for bamlanivimab, etesevimab, in the first six months of the year, they have sufficient inventory to go around, the new agreement gives them access to more doses, should any need arise.
According to the drugmaker, there is no impact expected on its financial outlook for 2021 from this agreement.
Lilly announced last week that 388,000 more doses of COVID-19, the drugmaker’s COVID-19-based antibody therapy, were purchased by the U.S. Government. This will allow it to pair with its existing supply of bamlanivimab.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.